Boukje C. Eveleens Maarse

Boukje C. Eveleens Maarse

Auto-generated profile, based on publicly available information

Boukje C. Eveleens Maarse

Centre for Human Drug Research Leiden The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
BMBoukje C Eveleens Maarse
Boukje C Eveleens Maarse
NCNicholas C Chesnaye
Nicholas C Chesnaye
RSRobbert Schouten
Robbert Schouten
WMWieneke M Michels
Wieneke M Michels
WBWillem Jan W Bos
Willem Jan W Bos
YMY. Meuleman
Y. Meuleman
Depressive symptoms are associated with adverse clinical outcomes in patients with end-stage kidney disease; however, few small studies have examined this association in patients with earlier phases of chronic kidney disease (CKD). We studied associations between baseline depressive symptoms and clinical outcomes in older patients with advanced CKD and examined whether these associations differed depending on sex. CKD patients (≥65 years; estimated glomerular filtration rate ≤20 mL/min/1.73 m2) were included from a European multicentre prospective cohort between 2012 and 2019. Depressive symptoms were measured by the five-item Mental Health Inventory (cut-off ≤70; 0–100 scale). Cox proportional hazard analysis was used to study associations between depressive symptoms and time to dialysis initiation, all-cause mortality and these outcomes combined. A joint model was used to study the association between depressive symptoms and kidney function over time. Analyses were adjusted for potential baseline confounders. Overall kidney function decline in 1326 patients was –0.12 mL/min/1.73 m2/month. A total of 515 patients showed depressive symptoms. No significant association was found between depressive symptoms and kidney function over time (P = 0.08). Unlike women, men with depressive symptoms had an increased mortality rate compared with those without symptoms [adjusted hazard ratio 1.41 (95% confidence interval 1.03–1.93)]. Depressive symptoms were not significantly associated with a higher hazard of dialysis initiation, or with the combined outcome (i.e. dialysis initiation and all-cause mortality). There was no significant association between depressive symptoms at baseline and decline in kidney function over time in older patients with advanced CKD. Depressive symptoms at baseline were associated with a higher mortality rate in men.

6 February 2024 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
BMBoukje C. Eveleens Maarse
Boukje C. Eveleens Maarse
HEHannah M. Eggink
Hannah M. Eggink
IWInes Warnke
Ines Warnke
SBSabina Bijlsma
Sabina Bijlsma
TBTim J. van Den Broek
Tim J. van Den Broek
FHFemke Hoevenaars
Femke Hoevenaars

22 February 2023 in Immunologic Research
Verified
Journal Article
Open access
PDF file
AVAliede E. in 't Veld
Aliede E. in 't Veld
HGHendrika Grievink
Hendrika Grievink
JPJohan L. van der Plas
Johan L. van der Plas
BMBoukje C. Eveleens Maarse
Boukje C. Eveleens Maarse
SKSebastiaan J. W. van Kraaij
Sebastiaan J. W. van Kraaij
MMMatthijs Moerland
Matthijs Moerland
Based on its wide range of immunosuppressive properties, hydroxychloroquine (HCQ) is used for the treatment of several autoimmune diseases. Limited literature is available on the relationship between HCQ concentration and its immunosuppressive effect. To gain insight in this relationship, we performed in vitro experiments in human PBMCs and explored the effect of HCQ on T and B cell proliferation and Toll-like receptor (TLR)3/TLR7/TLR9/RIG-I-induced cytokine production. In a placebo-controlled clinical study, these same endpoints were evaluated in healthy volunteers that were treated with a cumulative dose of 2400 mg HCQ over 5 days. In vitro, HCQ inhibited TLR responses with IC50s > 100 ng/mL and reaching 100% inhibition. In the clinical study, maximal HCQ plasma concentrations ranged from 75 to 200 ng/mL. No ex vivo HCQ effects were found on RIG-I-mediated cytokine release, but there was significant suppression of TLR7 responses and mild suppression of TLR3 and TLR9 responses. Moreover, HCQ treatment did not affect B cell and T cell proliferation. These investigations show that HCQ has clear immunosuppressive effects on human PBMCs, but the effective concentrations exceed the circulating HCQ concentrations under conventional clinical use. Of note, based on HCQ’s physicochemical properties, tissue drug concentrations may be higher, potentially resulting in significant local immunosuppression. This trial is registered in the International Clinical Trials Registry Platform (ICTRP) under study number NL8726.

8 January 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
CYChristina Yfanti
Christina Yfanti
BVBirgitte Vestbjerg
Birgitte Vestbjerg
JWJuliette Van'T Westende
Juliette Van'T Westende
NENils Edvardsson
Nils Edvardsson
LMLaia Meseguer Monfort
Laia Meseguer Monfort
AHAnders G. Holst
Anders G. Holst
Aims: AP30663 is a novel compound under development for pharmacological conversion of atrial fibrillation by targeting the small conductance Ca2+ activated K+ (KCa2) channel. The aim of this extension phase 1 study was to test AP30663 at higher single doses compared to the first‐in‐human trial.Methods: Sixteen healthy male volunteers were randomized into 2 cohorts: 6‐ and 8‐mg/kg intravenous single‐dose administration of AP30663 vs. placebo. Safety, pharmacokinetic and pharmacodynamic data were collected.Results: AP30663 was associated with mild and transient infusion site reactions with no clustering of other adverse events but with an estimated maximum mean QTcF interval prolongation of 45.2 ms (95% confidence interval 31.5–58.9) in the 6 mg/kg dose level and 50.4 ms (95% confidence interval 36.7–64.0) with 8 mg/kg. Pharmacokinetics was dose proportional with terminal half‐life of around 3 h.Conclusion: AP30663 in doses up to 8 mg/kg was associated with mild and transient infusion site reactions and an increase of the QTcF interval. Supporting Information support that the QTc effect may be explained by an off‐target inhibition of the IKr channel.

24 August 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
BMBoukje C. Eveleens Maarse
Boukje C. Eveleens Maarse
CGClaus Graff
Claus Graff
JKJørgen K. Kanters
Jørgen K. Kanters
MEMichiel J. van Esdonk
Michiel J. van Esdonk
MKMichiel J. B. Kemme
Michiel J. B. Kemme
PGPim Gal
Pim Gal
Aims: Hydroxychloroquine has been suggested as possible treatment for severe acute respiratory syndrome‐coronavirus‐2. Studies reported an increased risk of QTcF‐prolongation after treatment with hydroxychloroquine. The aim of this study was to analyse the concentration‐dependent effects of hydroxychloroquine on the ventricular repolarization, including QTcF‐duration and T‐wave morphology.Methods: Twenty young (≤30 y) and 20 elderly (65–75 y) healthy male subjects were included. Subjects were randomized to receive either a total dose of 2400 mg hydroxychloroquine over 5 days, or placebo (ratio 1:1). Follow‐up duration was 28 days. Electrocardiograms (ECGs) were recorded as triplicate at baseline and 4 postdose single recordings, followed by hydroxychloroquine concentration measurements. ECG intervals (RR, QRS, PR, QTcF, J‐Tpc, Tp‐Te) and T‐wave morphology, measured with the morphology combination score, were analysed with a prespecified linear mixed effects concentration–effect model.Results: There were no significant associations between hydroxychloroquine concentrations and ECG characteristics, including RR‐, QRS‐ and QTcF‐interval (P = .09, .34, .25). Mean ΔΔQTcF‐interval prolongation did not exceed 5 ms and the upper limit of the 90% confidence interval did not exceed 10 ms at the highest measured concentrations (200 ng/mL). There were no associations between hydroxychloroquine concentration and the T‐wave morphology (P = .34 for morphology combination score). There was no significant effect of age group on ECG characteristics.Conclusion: In this study, hydroxychloroquine did not affect ventricular repolarization, including the QTcF‐interval and T‐wave morphology, at plasma concentrations up to 200 ng/mL. Based on this analysis, hydroxychloroquine does not appear to increase the risk of QTcF‐induced arrhythmias.

25 June 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
AVAliede E. in 't Veld
Aliede E. in 't Veld
BMBoukje C. Eveleens Maarse
Boukje C. Eveleens Maarse
MJMaria J. Juachon
Maria J. Juachon
SMSoufian Meziyerh
Soufian Meziyerh
AVAiko P.J. de Vries
Aiko P.J. de Vries
MMMatthijs Moerland
Matthijs Moerland
The recommended immunosuppressive treatment after kidney transplantation consists of tacrolimus, mycophenolate mofetil, and low‐dose corticosteroids. Drug concentrations are monitored using therapeutic drug monitoring (TDM), which does not necessarily correlate with pharmacodynamic activity. To find the balance between optimal efficacy and minimal toxicity, it might be more informative to monitor patients' immunological status rather than drug concentrations. We selected a panel of T‐cell‐based immune assays, which were used for immunomonitoring of 14 stable kidney transplantation patients. Whole blood was incubated with a T‐cell stimulus, after which T‐cell proliferation, T‐cell activation marker expression and cytokine production were measured to study residual immune activity in vitro (before drug intake; drug added to the incubation) and ex vivo (after drug intake). T‐cell proliferation was completely suppressed in all patients over the full day, while IL‐2, IFN‐γ, CD71, and CD154 showed fluctuations over the day with a strong inhibition (75%–25%) at 2 h post‐dose. The level of inhibition was variable between patients and could not be related to pharmacokinetic parameters or the presence of regulatory or senescence immune cells. Moreover, the level of inhibition did not correlate with the in vitro tacrolimus drug effect as studied by incubating pre‐dose blood samples with additional tacrolimus. Overall, IL‐2, IFN‐γ, CD71, and CD154 seem to be good markers to monitor residual immune activity of transplantation patients. To evaluate the correlation between these pharmacodynamic biomarkers and clinical outcome, prospective observational studies are needed.